Just - Evotec Biologics
- Company typePrivate
- Founded2014
- HeadquartersSeattle, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
Just - Evotec Biologics firmographics
Firmographics- Name
- Just - Evotec Biologics
- Legal name
- Just - Evotec Biologics Inc.
- Website
- https://justbiotherapeutics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Just - Evotec Biologics industry classification
Industry- Product category
- Biologics Contract Development and Manufacturing (CDMO)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
Keywords
Where Just - Evotec Biologics is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Just - Evotec Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- CDMO Fee-for-Service Manufacturing: Traditional contract development and manufacturing organization services offering antibody discovery, development, process development and biomanufacturing on a fee-for-service basis.
- Technology Licensing: Licensing of continuous manufacturing technology to partners. Landmark deal with Sandoz for approximately $350 million including licensing and milestone payments potentially over $650 million plus royalties.
- Research Grants: Grant funding from foundations for global health applications. Gates Foundation funding for AI-driven antibody optimization across 10 projects over three years.
- Government Contracts: Multi-year programs with government agencies for biomanufacturing optimization. BARDA contract valued at up to $10 million for Ebola antibody manufacturing.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Just - Evotec Biologics product offering
Product offeringCore offering
Just - Evotec Biologics is a Contract Development and Manufacturing Organization (CDMO) offering development and cGMP manufacturing services for antibodies, next-generation biologics, and biosimilar products. The company applies proprietary end-to-end continuous manufacturing technology (J.Train platform) housed in modular J.POD facilities, integrated with the AI-driven J.MD molecular design platform, to produce biologics at higher productivity and lower cost of goods than traditional batch processes.
Product overview
Just - Evotec Biologics is a CDMO (Contract Development and Manufacturing Organization) offering development and cGMP manufacturing services for antibodies, next-generation biologics, and biosimilar products. The company operates an integrated platform architecture built around its core continuous biomanufacturing technology. Key products include J.POD (award-winning modular facility design for continuous processing), J.Train Continuous Platform (end-to-end continuous intensified manufacturing process achieving 10x productivity), and J.MD Molecular Design Platform (AI-driven computational technology for antibody optimization). The company provides complementary services including mAbs Optimization Solutions, Clinical Stage cGMP Manufacturing, Cell Line Development Solutions, CHO Perfusion Cell Culture Medium, Analytical Development, and Commercial Process Development. Two manufacturing sites in Seattle and Redmond, WA offer integrated services from cell line development through commercial manufacturing. Partnership models include traditional fee-for-service CDMO arrangements as well as co-development, integrated programs, and technology out-licensing opportunities.
Differentiator
Problem solved
Functional benefit
Products and services
- J.POD Modular Biomanufacturing Facility Modular clean-room biomanufacturing facility design that houses the company's highly automated continuous process; capable of producing up to two metric tons of product per year in a small footprint, used by pharmaceutical and biotech clients.
- J.Train Continuous Manufacturing Platform End-to-end continuous intensified manufacturing process platform for antibody and recombinant protein production using 500–2,000L single-use perfusion bioreactors, achieving 10x productivity of typical fed-batch processes; licensed to Sandoz for biosimilar manufacturing.
- J.MD Molecular Design Platform AI-driven computational platform for optimizing monoclonal antibody developability and reducing biotherapeutic manufacturing costs; used for global health applications and biotech clients seeking improved antibody candidates.
- mAbs Optimization Solutions Service for optimizing monoclonal antibodies through molecular design, developability assessment, and manufacturing process optimization, targeted at pharma/biotech clients seeking to reduce cost of goods.
- Clinical Stage cGMP Manufacturing Early clinical through commercial cGMP biologics manufacturing services including process development and validation, delivered from the company's Seattle and Redmond manufacturing sites for pharma and biotech clients.
- Cell Line Development Solutions Cell line development services for antibody and recombinant protein production, integrated with the company's continuous manufacturing platform for biotech and pharma clients.
- CHO Perfusion Cell Culture Medium Specialized perfusion cell culture medium optimized for continuous biomanufacturing processes, supporting high-density cell cultures in perfusion bioreactor systems for antibody and recombinant protein manufacturing.
Quantifiable outcome
- 10x productivity improvement over fed batch processes
- +4 more outcomes
Companies that use Just - Evotec Biologics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Just - Evotec Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Just - Evotec Biologics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- BARDA (Biomedical Advanced Research and Development Authority)coreJust-Evotec Biologics was selected by BARDA's Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) for a multi-year program to optimize biomanufacturing of monoclonal antibody therapeutics targeting Ebola and Sudan filovirus diseases. The agreement is valued at up to $10 million if all options are activated. The company will leverage its validated technology platforms for molecular optimization, cell line development, and manufacturing process development for antibodies from 2014 Ebola outbreak survivors.
- Bill & Melinda Gates FoundationcoreGates Foundation awarded a new grant to leverage Just-Evotec's J.MD molecular design platform for optimizing monoclonal antibody developability and reducing costs for biotherapeutics. The three-year investment funds 10 new projects targeting multiple global health disease indications in low- and middle-income countries. This extends an existing partnership that began in 2014, building on previous GMP manufacturing campaigns for RSV, Malaria, and HIV monoclonal antibodies.
- SandozcoreSandoz completed acquisition of Just-Evotec Biologics EU SAS including the Toulouse development and manufacturing site for approximately $350 million. The deal includes an indefinite license to Just-Evotec's continuous-manufacturing technology for biosimilars. This expands Sandoz's in-house drug substance development and manufacturing capabilities and positions the company to capture the projected $300 billion global biosimilars market. The landmark transaction with Sandoz is potentially worth over $650 million including licensing and milestone payments plus royalties.
Scale indicators7 records
Recent moves7 records
Expansion highlights4 records
Just - Evotec Biologics competitors and assessment
Company assessmentDirect peers
- WuXi Biologics: China-based global biologics CDMO with comprehensive mAb and bispecific development/manufacturing services. Comparable in end-to-end CDMO model and focus on accelerating biologic development timelines.
- Lonza Biologics: Largest global biologics CDMO offering mammalian cell culture development and cGMP manufacturing for mAbs and recombinant proteins. Directly comparable in target customer base, scale (multi-thousand liter fed-batch and continuous capabilities), and service breadth.
- Catalent (Novo Holdings): Major contract manufacturer with biologics capabilities including mammalian cell culture and fill-finish. Comparable as a large-scale biologics CDMO serving pharma and biotech clients globally.
- AGC Biologics: Global biologics CDMO offering mammalian and microbial cGMP manufacturing for mAbs, recombinant proteins, and cell/gene therapies. Comparable in scale and CDMO service model, with multiple global manufacturing sites.
- Samsung Biologics: Korea-based biologics CDMO providing end-to-end mAb and recombinant protein manufacturing services. Comparable as a full-service mammalian CDMO with large-scale cGMP capacity serving global biopharma.
- Rentschler Biopharma: Privately held European CDMO specializing in mammalian cell culture-based process development and manufacturing of mAbs and recombinant proteins. Comparable in mid-to-large scale biologics CDMO focus and target customer base.
- Fujifilm Diosynth Biotechnologies: Global CDMO providing process development and manufacturing for recombinant biologics and vaccines using mammalian and microbial systems. Comparable as a tier-one mammalian CDMO serving large biopharma clients.
Emerging players
- AbCellera Biologics: AI-driven antibody discovery and development company that is increasingly moving into manufacturing partnerships. Comparable as an AI/ML-native antibody company intersecting with biologics development, though more upstream-focused than Just-Evotec.
Broad incumbents
- Thermo Fisher Scientific (Patheon Biologics): Diversified life sciences tools and CDMO conglomerate with biologics manufacturing services through its Patheon network. Comparable in CDMO offerings but as part of a much broader portfolio including reagents, instruments, and clinical research.
- Boehringer Ingelheim BioXcellence: Biologics CDMO division of Boehringer Ingelheim providing mammalian cell culture and microbial manufacturing for biopharma. Comparable as a tier-one mammalian CDMO with cGMP capacity for mAbs and recombinant proteins.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Just - Evotec Biologics social profiles
Digital presenceJust - Evotec Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Just - Evotec Biologics leadership team
Management profileNumber of profiles
Profiles6 records
Just - Evotec Biologics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Just - Evotec Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Just - Evotec Biologics
What does Just - Evotec Biologics do?
Just - Evotec Biologics is a Contract Development and Manufacturing Organization (CDMO) offering development and cGMP manufacturing services for antibodies, next-generation biologics, and biosimilar products. The company applies proprietary end-to-end continuous manufacturing technology (J.Train platform) housed in modular J.POD facilities, integrated with the AI-driven J.MD molecular design platform, to produce biologics at higher productivity and lower cost of goods than traditional batch processes.
Is Just - Evotec Biologics a public or private company?
Just - Evotec Biologics is a private company. It is classified as corporate owned and is currently operating.
When was Just - Evotec Biologics founded?
Just - Evotec Biologics was founded in 2014. It employs 251 to 500 people.
Where is Just - Evotec Biologics based?
Just - Evotec Biologics is headquartered in Seattle, United States, in the North America region.
How does Just - Evotec Biologics make money?
Four revenue lines are on record. CDMO Fee-for-Service Manufacturing is the primary driver. The others are technology Licensing, research Grants and government Contracts.
Who are Just - Evotec Biologics's main competitors?
Direct peers on record are WuXi Biologics, Lonza Biologics, Catalent (Novo Holdings), AGC Biologics, Samsung Biologics, Rentschler Biopharma and Fujifilm Diosynth Biotechnologies. AbCellera Biologics is listed as an emerging player. Broad incumbents are Thermo Fisher Scientific (Patheon Biologics) and Boehringer Ingelheim BioXcellence.
Does Just - Evotec Biologics have an API?
No public API is recorded for Just - Evotec Biologics.
What industry is Just - Evotec Biologics in?
Just - Evotec Biologics's product category is Biologics Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 2836.